Related Experiment Videos
The neuroleptics as adjuvant analgesics
Journal of Pain and Symptom Management
|October 1, 1994
Summary
Neuroleptic drugs show limited efficacy as routine analgesics, with methotrimeprazine offering potential dose-related pain relief. Their use may be considered for refractory pain, but they are more established for managing agitation and nausea in cancer patients.
Area of Science:
- Pharmacology
- Pain Management
- Oncology
Background:
- Neuroleptic drugs have been controversially discussed as adjuvant analgesics.
- Evidence from controlled trials on their efficacy in pain relief is often conflicting.
Purpose of the Study:
- To evaluate the evidence for neuroleptic drugs as adjuvant analgesics.
- To determine the specific roles and limitations of neuroleptics in pain management and symptom control.
Main Methods:
- Systematic review of controlled trials and existing literature on neuroleptic drug efficacy in pain.
- Analysis of evidence for specific neuroleptic agents, including methotrimeprazine and butyrophenones.
- Assessment of neuroleptics' roles in managing associated symptoms like agitation, delirium, and nausea.
Main Results:
- Controlled trials do not support the routine use of neuroleptics for reliable analgesia.
- Methotrimeprazine shows evidence of dose-related analgesia comparable to opioids, but routine use is not advised.
- Insufficient evidence exists for butyrophenone neuroleptics as adjuvant analgesics.
- Neuroleptics are effective in managing agitation, delirium, and nausea, especially in cancer patients.
Conclusions:
- Neuroleptic drugs lack robust evidence for routine use as adjuvant analgesics.
- Methotrimeprazine may offer specific analgesic benefits but requires cautious application.
- Neuroleptics are valuable for managing non-pain symptoms like agitation and nausea, particularly in palliative care settings.